Academic Journal
Small Interfering RNA (siRNA) in Dyslipidemia: A Systematic Review on Safety and Efficacy of siRNA.
| Τίτλος: | Small Interfering RNA (siRNA) in Dyslipidemia: A Systematic Review on Safety and Efficacy of siRNA. |
|---|---|
| Συγγραφείς: | Alla, Sai Santhosha Mrudula, Shah, Dhruv Jayeshkumar, Meyur, Shourya, Agarwal, Pahel, Alla, Deekshitha, Moraboina, Sai Lokesh, Ghadvaje, Gayatri Vijay, Bayeh, Ruth Getaneh, Malireddi, Aparna, Shajan, Tess, Vineetha, Bodipudi, Prudhvi, Thalvayapati Sai, Biziyaremye, Patrick |
| Πηγή: | Journal of Experimental Pharmacology; May2025, Vol. 17, p249-267, 19p |
| Θεματικοί όροι: | RNA interference, Small interfering RNA, Internet servers, Diabetes, Apolipoproteins |
| Περίληψη: | Introduction: RNA interference (RNAi) therapy represents an evolving advancement in the management of dyslipidemia. One prominent form of RNAi therapy is small interfering RNA (siRNA), which has emerged as a promising therapeutic strategy. This study aims to critically analyze the efficacy and safety of siRNA in the treatment of dyslipidemia. Methods: PubMed, Scopus, and Web of Science servers were used to conduct a systematic search in compliance with the PRISMA guidelines. Results: A total of 20 studies with 6651 participants were included in the analysis. The drugs used in the studies were. Inclisiran led to a notable 44.09% reduction in LDL and 37.5% in apolipoprotein levels among individuals with hypercholesterolemia. In hyperlipoproteinemia(a), therapies like Lepodisiran and Olpasiran achieved a 75.69% drop in apolipoproteins and 16.25% in LDL. For hypertriglyceridemia, agents such as ARO-APOC3 and Plozasiran showed over 50% reductions in both VLDL and triglycerides. In mixed hyperlipidemia and chylomicronemia, Plozasiran significantly reduced triglycerides by up to 79% and apolipoproteins by 87.5%. The 5 most common adverse effects reported were nasopharyngitis, diabetes mellitus (including new-onset diabetes mellitus and worsening diabetes mellitus), injection site adverse effects, back pain, and hypertension. Conclusion: In conclusion, the benefits of siRNA therapy in dyslipidemia management appear to outweigh its potential drawbacks, demonstrating promising efficacy and safety profiles. However, further research is necessary to fully understand its long-term effects and optimize its therapeutic potential. [ABSTRACT FROM AUTHOR] |
| Copyright of Journal of Experimental Pharmacology is the property of Dove Medical Press Ltd and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Βάση Δεδομένων: | Complementary Index |
καταχωρήστε σχόλιο πρώτοι!